ACM
PHAT icon

Aster Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Aster Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.51K Buy
+508
New +$5.8K ﹤0.01% 715
2025
Q1 		– Sell
-15
Closed -$122 – 1582
2024
Q4 		$122 Sell
15
-30
-67% -$372 ﹤0.01% 1069
2024
Q3 		$814 Buy
+45
New +$629 ﹤0.01% 1031

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Aster Capital Management's PHAT Position: Q2 2026 in Review

Aster Capital Management opened a new position in Phathom Pharmaceuticals (PHAT) in Q2 2026: 508 shares worth $5.51K. The stake represents ﹤0.01% of the portfolio and ranks #715 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in PHAT as recently as Q4 2024.

Aster Capital Management first reported a position in PHAT in Q3 2024 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Aster Capital Management held 508 shares of Phathom Pharmaceuticals worth $5.51K as of Q2 2026.
  • Phathom Pharmaceuticals was a new Aster Capital Management position in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #715 holding.
  • Aster Capital Management first reported a position in Phathom Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.